Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risdiplam in Type 1 Spinal Muscular Atrophy.
Baranello G, Darras BT, Day JW, Deconinck N, Klein A, Masson R, Mercuri E, Rose K, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Seabrook T, Fontoura P, Servais L; FIREFISH Working Group. Baranello G, et al. N Engl J Med. 2021 Mar 11;384(10):915-923. doi: 10.1056/NEJMoa2009965. Epub 2021 Feb 24. N Engl J Med. 2021. PMID: 33626251 Clinical Trial.
Safety and efficacy of risdiplam in patients with type 1 spinal muscular atrophy (FIREFISH part 2): secondary analyses from an open-label trial.
Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Servais L, Xiong H, Zanoteli E, Baranello G, Bruno C, Day JW, Deconinck N, Klein A, Mercuri E, Vlodavets D, Wang Y, Dodman A, El-Khairi M, Gorni K, Jaber B, Kletzl H, Gaki E, Fontoura P, Darras BT; FIREFISH Study Group. Masson R, et al. Lancet Neurol. 2022 Dec;21(12):1110-1119. doi: 10.1016/S1474-4422(22)00339-8. Epub 2022 Oct 14. Lancet Neurol. 2022. PMID: 36244364 Clinical Trial.
Risdiplam-Treated Infants with Type 1 Spinal Muscular Atrophy versus Historical Controls.
Darras BT, Masson R, Mazurkiewicz-Bełdzińska M, Rose K, Xiong H, Zanoteli E, Baranello G, Bruno C, Vlodavets D, Wang Y, El-Khairi M, Gerber M, Gorni K, Khwaja O, Kletzl H, Scalco RS, Fontoura P, Servais L; FIREFISH Working Group. Darras BT, et al. N Engl J Med. 2021 Jul 29;385(5):427-435. doi: 10.1056/NEJMoa2102047. N Engl J Med. 2021. PMID: 34320287
Efficacy of TNF-Alpha Inhibitors to Control Inflammation and Prevent Secondary Complications in Non-Infectious Uveitis: A Real-Life Experience from Switzerland.
Fuchs D, Bograd A, Pfister IB, Bächtiger J, Spindler J, Hoogewoud F, Gugleta K, Böni C, Guex-Crosier Y, Garweg JG, Tappeiner C. Fuchs D, et al. Among authors: gugleta k. Ocul Immunol Inflamm. 2023 Oct 5:1-6. doi: 10.1080/09273948.2023.2263095. Online ahead of print. Ocul Immunol Inflamm. 2023. PMID: 37797183
Swiss Multicenter Ab Interno XEN45 Gel Stent Study: 2-Year Real-World Data.
Papazoglou A, Höhn R, Schawkat M, Tappeiner C, Iliev M, Gugleta K, Saletta G, Wiencierz A, Wagels B, Todorova MG, Krzyzanowska I, Töteberg-Harms M, Tschopp M. Papazoglou A, et al. Among authors: gugleta k. Ophthalmol Ther. 2024 Jun;13(6):1513-1525. doi: 10.1007/s40123-024-00917-y. Epub 2024 Apr 6. Ophthalmol Ther. 2024. PMID: 38581605 Free PMC article.
Current practice in the management of ocular toxoplasmosis.
Yogeswaran K, Furtado JM, Bodaghi B, Matthews JM; International Ocular Toxoplasmosis Study Group; Smith JR. Yogeswaran K, et al. Br J Ophthalmol. 2023 Jul;107(7):973-979. doi: 10.1136/bjophthalmol-2022-321091. Epub 2022 Feb 23. Br J Ophthalmol. 2023. PMID: 35197262
Analysis of risk factors for long-term glaucomatous damage development.
Gross S, Gugleta K, Turksever C, Ledolter A, Kochkorov A, Flammer J, Orgul S. Gross S, et al. Among authors: gugleta k. Klin Monbl Augenheilkd. 2014 Apr;231(4):335-9. doi: 10.1055/s-0034-1368222. Epub 2014 Apr 25. Klin Monbl Augenheilkd. 2014. PMID: 24771162
90 results